Biodesix (BDSX) Accounts Payables (2019 - 2026)

Biodesix (BDSX) has 8 years of Accounts Payables data on file, last reported at $3.7 million in Q1 2026.

• Quarterly Accounts Payables rose 24.82% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (up 24.82% YoY) and the FY2025 annual result came in at $3.1 million, up 40.38% from the prior year.
• Accounts Payables improved to $3.7 million in Q1 2026, from $3.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $3.7 million in Q1 2026 to a low of $1.6 million in Q1 2023.
• A 5-year average of $2.6 million and a median of $2.9 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables sank 43.42% — and 2024, when it surged 105.57%.
• Tracing BDSX's Accounts Payables over 5 years: stood at $1.7 million in 2022, then soared by 73.83% to $2.9 million in 2023, then declined by 25.09% to $2.2 million in 2024, then soared by 40.38% to $3.1 million in 2025, then rose by 18.54% to $3.7 million in 2026.
• The last three Accounts Payables figures came in at $3.7 million (Q1 2026), $3.1 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.